[Disclosure] Celltrion (068270) Secures US FDA Final Marketing Authorization for ‘Actemra Biosimilar (CT-P47)’ Avtozma

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-01-31

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has obtained final marketing authorization from the US Food and Drug Administration (FDA) for ‘Avtozma’ (a biosimilar to Actemra), and plans to sell the product across the United States through its local US subsidiaries.

📊 1. [Key Disclosure Content & Key Metrics Summary]

• Authorized Brand & Substance: Avtozma (CT-P47, Actemra biosimilar) / Active substance: Tocilizumab.
• Approved Indications: Secured final marketing approval from the US FDA for the following 5 indications:
  • Rheumatoid Arthritis
  • Giant Cell Arteritis
  • Systemic Juvenile Idiopathic Arthritis
  • Polyarticular Juvenile Idiopathic Arthritis
  • Coronavirus Disease 2019
• Key Administrative Timeline:
  • Initial Application Date: January 26, 2024 (Local time)
  • Final Marketing Authorization Date: January 24, 2025 (Local time)
• Regulatory Body: US Food and Drug Administration (FDA)
• Commercialization Plan: Celltrion plans to sell Avtozma (CT-P47) across the United States through its local US subsidiaries.

📈 2. [Expert View: What This Disclosure Means for Investors]

• Acquisition of Official US Marketing Rights: Final marketing authorization signifies the transition from clinical development to official commercial clearance, allowing the product to be sold in the US market for the approved 5 indications.
• Regulatory Timeline Clearance: Having completed the regulatory review approximately one year after the initial application in January 2024, the product has officially cleared the FDA’s approval process.
• Launch Execution by Local Subsidiaries: As the approval is secured, the future timeline for revenue translation will depend on the subsequent distribution and marketing plans carried out by the local US subsidiaries to sell the product across the country.

📝 Editor’s Comment (by K-STOCK Editor)

The final marketing authorization granted by the US FDA marks the successful completion of the development phase and provides the official clearance required to enter the US commercial market. Securing approval for the 5 specified indications establishes the legal baseline for commercial operations.

With the regulatory approval achieved, the focus of future evaluation shifts toward the commercialization and launch execution by the local US subsidiaries. As outlined in the disclosure, the product will be sold through local US subsidiaries, making their distribution schedules and commercial preparations the key parameters to monitor.

Going forward, key metrics to track include the specific launch timelines established by the local US subsidiaries, the progress of insurance and pricing listings, and the general supply-demand trends following commercial release.

📢 Disclaimer & Source Information

Source: This content has been newly structured and written based on official disclosure data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.